- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC
May 31st 2024, 12:00pm
Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
May 30th 2024, 4:25pm
Frontline rivoceranib plus camrelizumab continued to show a significant improvement in OS vs sorafenib in advanced unresectable hepatocellular carcinoma.
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
May 23rd 2024, 9:51pm
Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
May 23rd 2024, 9:00pm
Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
May 23rd 2024, 9:00pm
Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies
May 23rd 2024, 9:00pm
An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.
Long-Term Findings Clarify Role of Estrogen Therapy on Ovarian/Endometrial Cancer Incidence
May 23rd 2024, 9:00pm
Treatment with CEE alone was associated with increased ovarian cancer incidence and mortality rates in postmenopausal women who had undergone hysterectomy.
Addressing Research Into the Association Between Tumor Mutations and Responses in RCC
May 21st 2024, 10:10pm
Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.
Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer
May 20th 2024, 5:00pm
Rebecca Porter, MD, PhD, discusses mirvetuximab soravtansine plus pembrolizumab in serous endometrial cancer and future directions for ADCs in the space.
Dr Liu Previews ASCO 2024 Lung Cancer Data
May 17th 2024, 8:52pm
Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
May 17th 2024, 8:52pm
S. Vincent Rajkumar, MD, discusses highly anticipated abstracts in multiple myeloma that will be presented at the 2024 ASCO Annual Meeting.
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
May 17th 2024, 8:10pm
ESMO Breast Cancer Virtual Meeting
Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
May 17th 2024, 7:00pm
ESMO Breast Cancer Virtual Meeting
PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.
Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer
May 17th 2024, 6:00pm
ESMO Breast Cancer Virtual Meeting
Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
May 16th 2024, 8:33pm
ESMO Breast Cancer Virtual Meeting
Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
May 16th 2024, 7:50pm
ESMO Breast Cancer Virtual Meeting
Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer
May 16th 2024, 6:59pm
ESMO Breast Cancer Virtual Meeting
Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
May 16th 2024, 4:04pm
Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
May 15th 2024, 9:49pm
ESMO Breast Cancer Virtual Meeting
Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
May 15th 2024, 8:56pm
ESMO Breast Cancer Virtual Meeting
Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.